~~<i id='26B8BF9EA0'><strike id='26B8BF9EA0'><tt id='26B8BF9EA0'><pre id='26B8BF9EA0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：leisure time 2025-10-01 17:19:08 - browse：9499

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Exact Sciences stock tumbles despite strong cancer detection sales

focus

knowledge

hotspot

focus

explore

knowledge

AlexHogan/STATWASHINGTON—Healthcarecostsaregettingsohighthatpricesareliterallyrunningoffofthepage.Me

WSS

Dogs on Prozac: What pet anti

How faith leaders like me can help address America's obesity epidemic

Teladoc has a new CEO, but challenges remain the same

Statins may not be needed by millions of people, study suggests

Exact Sciences stock tumbles despite strong cancer detection sales

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

entertainment

explore

focus

As demand for Covid shots wanes, Moderna seeks its next success

Health care needs a new profession: neuroimaging counseling

Peter Hotez and the public health issue of online harassment

How faith leaders like me can help address America's obesity epidemic

Supreme Court strikes down use of affirmative action

Statins may not be needed by millions of people, study suggests

BioMarin wins approval for gene therapy to treat hemophilia A

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

How one medical school became remarkably diverse

Pharma companies must ensure equitable access to obesity drugs

knowledge

Exact Sciences stock tumbles despite strong cancer detection sales

MassMutual is introducing free genetic testing for members

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Deposition: Sackler embraced plan to conceal OxyContin’s strength

California wildfire smoke linked to 52,000 early deaths, study says

Readers discuss the intersection of pregnancy and addiction

hotspot

focus

explore

knowledge